Arash Keshavarzi

Bio

Arash Keshavarzi, PhD, has a background in Molecular Biology and AI drug discovery, with experience bridging AI and biotechnology. He used to be the CSO of Nucleus Genomics, a company that has raised over $30 million in funding from prominent investors including Founders Fund. He is the Co-founder of Lumos Bio, a UCSF spin-off focused on pioneering RNA-targeting cancer therapeutics, and also a co-founder of Entelligent.ai, driving innovation in AI driven intelligence. Additionally, Arash is actively involved in venture capital and investment as an Investment Fellow at Mubadala Capital, where he builds investment thesis, sources deals, and helps both biotech and AI teams. His career uniquely blends deep scientific expertise, entrepreneurial acumen, and strategic investment insights.

He has published over 10 academic papers in AI Therapeutics fields
He has published two book chapter in AI medicine
He has two patents in AI for small molecule drug discovery, one approved, one pending

Stanford Advisors

• Euan Ashley, Postdoctoral Faculty Sponsor

Patents

• Arash Keshavarzi. "United States Patent US12040094B2 Artificial intelligence-based methods for early drug discovery and related training methods", USPTO, Jul 16, 2024
• Arash Keshavarzi Arshadi. "United States Patent WO/2023/154588 DEEP-LEARNING BASED METHODS FOR VIRTUAL SCREENING OF MOLECULES FOR MICRO RIBONUCLEIC ACID (MIRNA) DRUG DISCOVERY", WIPO, Aug 17, 2023